Nazartinib; EGF816; NVS-816

Inoa Kimia:

(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)akā-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)- 2-methylisonicotinamide

SMILES Code:

O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4

Code InChi:

InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5, 8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1

Ki InChi:

IOMMMLWIABWRKL-WUTDNEBXSA-N

Hua'ōlelo:

Nazartinib ,EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2

Hiki ke hoʻoheheʻe:Hiki ke hoʻoheheʻe ʻia ma DMSO

Waihona:0 - 4°C no ka wā pōkole (nā lā i nā pule), a i ʻole -20°C no ka wā lōʻihi (mau mahina)

wehewehe:

ʻO Nazartinib, ka mea i ʻike ʻia ʻo EGF816 a me NVS-816, he mea hiki ke hoʻololi ʻia, ke kolu o ka hanauna, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, me ka hana antineoplastic. Hoʻopaʻa like ʻo EGF816 a hoʻopaʻa i ka hana o nā ʻano mutant o EGFR, me ka mutant T790M EGFR, no laila e pale ana i ka hōʻailona ʻana o ka EGFR-mediated. Hiki paha i kēia ke hoʻoulu i ka make cell a keʻakeʻa i ka ulu ʻana o ka maʻi maʻi i loko o nā cell tumor-overexpressing EGFR. Kāohi ʻo EGF816 i nā ʻano like ʻole o EGFR me T790M, kahi hoʻololi kūʻē kūʻē i loaʻa lua, a loaʻa paha nā pōmaikaʻi lapaʻau i nā ʻōpū me ka T790M-mediated resistance ke hoʻohālikelike ʻia me nā mea hoʻopaneʻe EGFR tyrosine kinase.

Pahuhopu: EGFR